Strategic Financing ILiAD has recently raised substantial Series B funding ($115M) and carries an overall funding total of $183M, signaling strong investor confidence and financial capacity to support large-scale clinical trials and partnerships. This creates timing opportunities for high-value collaborations and joint development agreements.

Phase 3 Readiness The company is positioned as Phase 3 ready with ongoing and planned pivotal trials for the BPZE1 intranasal pertussis vaccine, presenting a clear path for contract research, endpoint consulting, regulatory support, and scaled manufacturing partnerships.

Clinical Collaboration Recent and ongoing partnerships with Emmes Group and hVivo indicate openness to CRO/partner ecosystems for large Phase 3 human challenge studies and trial execution, suggesting opportunities for sponsored research, data management, and trial logistics services.

Regulatory Momentum Achievements such as the MHRA Innovation Passport designation and publications in reputable journals (The Lancet) underscore regulatory credibility and scientific validation, enabling outreach to regulatory affairs consultants, global trial sites, and payer relationships.

Global Market Readiness With a focus on intranasal pertussis vaccination and leadership in a potentially large preventive market, there are opportunities to engage manufacturing, supply chain, and distribution partners, as well as regional market access and commercialization allies for eventual product rollout.